AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.

AbbVie invests $380m in North Chicago for API manufacturing, creating 300 jobs, boosting US R&D, and expanding domestic ...

Feb 23 (Reuters) - AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient ...

AbbVie’s $100 billion splurge on domestic manufacturing and R&D is continuing to come into focus, this time with a $380 million investment in two new active pharmaceutical ingredient manufactur | The ...

With a substantial manufacturing base already locked down in China, CRDMO BioDuro is taking a short jaunt down to Taiwan for its latest drug ingredients production play.  | BioDuro, headquartered in ...

As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened regulatory scrutiny, the role of the top pharmaceutical API manufacturer has taken on ...

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

Part of AbbVie’s vow to invest $100 billion in the U.S. over the next decade, the two Illinois facilities will make active ingredients for next-generation neuroscience and obesity drugs when they ...

AbbVie is investing $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its headquarters campus in North Chicago. Construction is set to begin in spring 2026, ...

Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety ...

Western Digital (WDC) earns a strong buy rating, targeting a $454 fair value (~68% upside) driven by structural ...

As sponsors advanced more niche and personalized modalities, manufacturers were pushed to adopt holistic approaches to safety ...